Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil) in HIV-infected Adolescents and Young Adults vs. Healthy Adolescents and Young Adults: Non-randomized Controlled Clinical Trial.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-002193-23).
- 25 Jan 2012 New trial record